Skip to main content

Clinical Trials Using Exemestane

Review the clinical trials studying exemestane on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-24 of 24

Testing Whether Hormone Therapy with Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy with Ribociclib for the Treatment of High Anatomic Stage Breast Cancer with Low Recurrence Risk, The RxFINE-Low Trial
Status: Active
Location: 140 locations
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Status: Active
Location: 68 locations
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
Status: Active
Location: 32 locations
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Status: Active
Location: 22 locations
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Status: Active
Location: 22 locations
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Status: Active
Location: 21 locations
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Status: Active
Location: 18 locations
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Status: Active
Location: 14 locations
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Status: Active
Location: 15 locations
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Status: Active
Location: 14 locations
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Status: Active
Location: 10 locations
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Status: Active
Location: 7 locations
A Study Using ctDNA to Guide Treatment for People with HER2-positive Breast Cancer, HERizon-Breast Trial
Status: Active
Location: 7 locations
Abemaciclib in Combination with Endocrine Therapy for the Treatment of Older Patients with Hormone Receptor Positive Metastatic Breast Cancer
Status: Active
Location: 6 locations
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
Status: Active
Location: 5 locations
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Location: 3 locations
Neoadjuvant Endocrine Therapy to Improve Surgical Outcomes in Stage II-III ER+ HER2- Invasive Lobular Breast Cancer
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Medication Switch versus Guideline-directed Intervention (Side Effect Management) in Reducing Side Effects of Aromatase Inhibitors in Estrogen Receptor Positive HER2 Negative Breast Ductal Carcinoma In Situ and Stage I-III Invasive Breast Cancer, SWIVEL Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: University of Texas Health Science Center at San Antonio, San Antonio, Texas
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study
Status: Enrolling by Invitation
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.
Status: Active
Location: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York